From June 9 – 11, 2025, FCF hosted its sixth Fibrolamellar Scientific Summit bringing together the fibrolamellar research community to share research knowledge and to collaborate in the search for a cure.
To encourage the sharing of unpublished information, the scientific discussions in the main session were open only to researchers who have signed a multi-party non-disclosure agreement. However, the event’s introductory keynote discussion (June 9, 2025 from 8 – 9 pm ET) was open for virtual participation by the entire fibrolamellar community – patients, caregivers, clinicians and researchers.
The video below, the Summit’s introductory keynote, is a panel discussion exploring “Oncogene Targeted Immune Therapy in FLC”. It discusses and shares the great progress now being made in targeted immunotherapy against FLC. It features two clinician/researchers leading groundbreaking clinical trials of therapeutic vaccines against FLC’s fusion oncogene, and a patient participating in one of the active trials. Included are:
- Mark Furth, PhD, Chief Science Officer, FCF (moderator)
- Juliane Walz, MD, University of Tübingen
- Mark Yarchoan, MD, Johns Hopkins University
- Molly Hones, FLC patient and clinical trial participant.